CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of “Moderate Buy” by Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has earned an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $8.3571.

A number of research firms have commented on CAMP. Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Zacks Research cut CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Leerink Partners increased their price target on CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Finally, Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a research report on Tuesday, April 14th. They set a “buy” rating and a $7.00 price objective on the stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CAMP. Bank of America Corp DE boosted its position in shares of CAMP4 Therapeutics by 141,700.0% during the 1st quarter. Bank of America Corp DE now owns 31,196 shares of the Wireless communications provider’s stock valued at $138,000 after acquiring an additional 31,174 shares during the last quarter. SummitTX Capital L.P. acquired a new stake in CAMP4 Therapeutics during the first quarter worth about $1,497,000. Janus Henderson Group PLC raised its stake in CAMP4 Therapeutics by 35.9% during the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after purchasing an additional 1,666,666 shares during the period. EcoR1 Capital LLC purchased a new position in CAMP4 Therapeutics during the fourth quarter worth about $1,992,000. Finally, Balyasny Asset Management L.P. acquired a new position in CAMP4 Therapeutics in the 4th quarter valued at about $14,938,000.

CAMP4 Therapeutics Stock Down 3.9%

Shares of CAMP opened at $3.19 on Friday. CAMP4 Therapeutics has a 52-week low of $1.32 and a 52-week high of $7.75. The stock has a market cap of $165.66 million, a PE ratio of -1.35 and a beta of 0.10. The firm’s fifty day moving average is $4.21 and its two-hundred day moving average is $4.51.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). The business had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. As a group, research analysts anticipate that CAMP4 Therapeutics will post -0.84 earnings per share for the current year.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.